Senator Warren urged the US Patent and Trademark Office to carefully review Merck's Keytruda

Published Date: 02 Mar 2023

U.S. Senator Elizabeth Warren has sent a letter to the nation's leading patent attorney asking for further review of Merck's new patent application for its cancer drug Keytruda, which seeks to block the drug. , he said.

Read Full News

Latest News

Where Have All the Leaders Gone? PAs Want to Step Up

Many PAs are well qualified for leadership roles, but organizational barriers and limited opportunities continue to stand in the way.

CMS Proposes Major Medicare Physician Payment Overhaul to Boost Primary Care

The Centers for Medicare & Medicaid Services on Tuesday proposed changes to Medicare's decades-old physician payment system, saying the ⁠updates would support the Trump...

Married to Medicine: The Other Side of the Story

Being married to a doctor isn’t the easiest job. These doctors’ spouses share what it’s like and where to get support.

Cigna Invests $100 Million in New AI-powered Specialty Pharmacy Program

Cigna said on Wednesday its health services unit Evernorth has launched a new ⁠AI-powered specialty pharmacy program to reduce the time it takes to process prescriptions and...

Resident Doctors in England Vote for UK Government's Pay Offer, Ending Strikes

Resident doctors in England have voted to accept the government's latest pay and job offer, their ⁠union said on Monday, bringing an end to a long-running industrial dispute...

Democratic-led States Sue Over Trump Administration's Medicaid Work Requirement Rule

A coalition of Democratic-led states sued on Monday to block a Trump administration rule implementing new work requirements for Medicaid recipients, ⁠arguing it unlawfully...

Todays Updates

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

FDA Approves New ROS1 Inhibitor for NSCLC

The newly approved inhibitor is for patients who previously received another drug of the same class.

Todays Updates

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

FDA Approves New ROS1 Inhibitor for NSCLC

The newly approved inhibitor is for patients who previously received another drug of the same class.

Latest News

Many PAs are well qualified for leadership roles, but organizational barriers and limited opportunities continue to stand in the way.

The Centers for Medicare & Medicaid Services on Tuesday proposed changes to Medicare's decades-old physician payment system, saying the ⁠updates would support the Trump...

Being married to a doctor isn’t the easiest job. These doctors’ spouses share what it’s like and where to get support.

Cigna said on Wednesday its health services unit Evernorth has launched a new ⁠AI-powered specialty pharmacy program to reduce the time it takes to process prescriptions and...

Resident doctors in England have voted to accept the government's latest pay and job offer, their ⁠union said on Monday, bringing an end to a long-running industrial dispute...

A coalition of Democratic-led states sued on Monday to block a Trump administration rule implementing new work requirements for Medicaid recipients, ⁠arguing it unlawfully...

News All Time

What Your ZIP Code Is Costing You

Forget salary. The cities winning the physician satisfaction race are playing a completely different game.

How NPs Are Navigating Prior Authorization Coverage Barriers

The same hurdles facing physicians slow treatment for nurse practitioners’ patients, and the impact on care continues.

US FDA Issues Recall Of Boston Scientific Heart Devices

Boston Scientific has issued an urgent recall to correct several heart devices after ⁠the U.S. Food and Drug Administration classified the action as its most serious recall,...

Delays in Visa Program Threaten Hundreds of Doctors

Prolonged HHS J-1 waiver backlogs leave hundreds of foreign-trained doctors facing departure this summer, threatening care in underserved areas, immigration attorneys warn.

AstraZeneca to Invest $405 Million in Britain After US-UK Pharma Deal

Prime Minister Keir Starmer said on Wednesday that Britain's biggest company AstraZeneca would invest 300 million pounds ($405 ⁠million) in the country, after pausing...

Europe Risks Falling Behind in Medicine Race, Roche CEO

Europe risks falling behind the US and China in pharma innovation because of bureaucracy and government policies threatening ⁠jobs, Roche CEO Thomas Schinecker warns.

US Health Regulators to Speed Up Medicare Device Coverage

U.S. health regulators announced a new program to speed up Medicare coverage for certain medical devices on ⁠Thursday, saying it would cut reimbursement timelines to as...

Germany Risks Missing Out on New Drugs, AstraZeneca CEO Says

AstraZeneca's CEO said Germany risks missing out on new drugs that ⁠the drugmaker plans to launch if the nation sticks with plans to keep pharmaceutical spending in check.

U.S. to Ask States to Revalidate "high-risk" Medicaid Providers

Mehmet Oz, who heads the agency that runs the U.S. Medicare and ⁠Medicaid healthcare programs, said on Tuesday the Trump administration plans to ask all ⁠50 states to...

US FDA Warns Medline Over Defective Heart Procedure Syringes

The U.S. Food and Drug Administration has told medical device maker Medline that its syringes used in heart procedures ⁠are defective and warned the company of penal actions.

Swiss Industry Body Says US Tariffs on Pharmaceuticals Will Harm Patients

U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, ⁠supply chains and ultimately will harm patients, Switzerland's...

The ACA Subsidy Gap and Its Toll on Primary Care

When the ACA’s subsidy credits expired at the end of 2025, physicians knew patient volume and overall revenue would tank. How are doctors faring?

Karyopharm's Drug Meets One Of Two Goals in Blood Cancer Trial

Karyopharm Therapeutics said on Tuesday its therapy led to significant reduction in spleen size in a late-stage ⁠study of patients with a rare blood cancer, meeting only one...

Match Day Traditions Are Evolving

Opening the Match Day envelope with other med students is a once-in-a-lifetime event that most students want to celebrate together, but private options are good too.

Getting The Right Signal: Does Program Signaling Work?

Designed to curb application inflation and help mid-tier candidates, signaling is now the ‘make-or-break’ metric for a match. But is it working or creating new problems?

US Proposes Easing Limits on Cancer-causing Gas Used to Clean Medical Devices

The Trump administration is proposing to lift some limits on the use of ethylene oxide, a carcinogenic gas used ⁠for sterilization, saying previous constraints imposed under...

Recommended News For You

Charles III, King of Kings, is Cancerous.

Prostate cancer 'is not a death knell': Early detection and personalized care improve outcomes, study shows

Chemicals in Sewage Sludge Fertilizer Pose Cancer Risk, EPA Says

recognizing the mechanism by which the replication of the host cell is outperformed by the skin cancer virus.

In Biochemically Recurrent Nonmetastatic Prostate Cancer, Apalutamide Presents Its Argument.

Adjunctive Cannabis Extract Improves Nausea-Vomiting Prevention in Cancer Patients

Radiation therapy can promote amphiregulin, which increases growth of metastases

Recommended Articles For You

Seeing the Unseen: Examining Chancroid Through Images 

Multiple Myeloma: Understanding the Basics  

Unlocking the Potential of Palbociclib: A Comprehensive Overview 

The Pivotal Role of Telomerase in Breast Cancer Therapy Resistance and Treatment Strategies 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Nearly 6 Million Deaths From Five Major Cancer Types Averted Since 1975

2.

Researchers Challenge USPSTF's Lung Cancer Screening Criteria

3.

Prostate cancer Q&A: Improving detection and reducing overtreatment

4.

Diet and Prostate Cancer; TTFields OK'd for NSCLC; Cancer Studies Retracted

5.

How 7,000 steps a day could help reduce your risk of cancer

1.

MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed

2.

Targeted Approaches to Breast Cancer Liver Metastases: Surgery, Ablation, and Survival Insights

3.

How is Digital Innovation Revolutionizing Gynecologic Oncology Treatment and Patient Engagement?

4.

Comprehensive Applications in Oncology and Quality Improvement

5.

Apheresis vs. IVMP in Cancer Treatment: A Tale of Two Titans

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Preventing Blood Clots: The Importance of Venous Thromboembolism Management

2.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

3.

Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

5.

First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot